Custom Manufacturing, Project Outsourcing, your Trusted Partner from China
At NINGBO INNO PHARMCHEM CO.,LTD., we are passionate about the science that drives pharmaceutical innovation. Ertugliflozin L-Pyroglutamic Acid, a compound we supply, represents a significant advancement in the treatment of type 2 diabetes. Its therapeutic power lies in its specific mechanism of action as an inhibitor of the sodium-dependent glucose cotransporter 2 (SGLT2).
The human body has a remarkable system for filtering blood and reabsorbing essential substances like glucose in the kidneys. Normally, over 90% of filtered glucose is reabsorbed back into the bloodstream via SGLT2 transporters. In individuals with type 2 diabetes, this reabsorption process, along with other factors, contributes to elevated blood glucose levels (hyperglycemia). Ertugliflozin, derived from Ertugliflozin L-Pyroglutamic Acid, directly targets this process. By selectively inhibiting SGLT2, it reduces the amount of glucose that the kidneys reabsorb, thereby increasing glucose excretion in the urine.
This unique Ertugliflozin mechanism of action leads to a reduction in both fasting and postprandial blood glucose levels, contributing to improved glycemic control. Unlike some other diabetes medications, SGLT2 inhibitors like Ertugliflozin do not primarily rely on increasing insulin secretion, which can reduce the risk of hypoglycemia (dangerously low blood sugar). This makes them a valuable addition to the therapeutic arsenal for type 2 diabetes management.
The L-pyroglutamic acid component often plays a role in forming a stable cocrystal with Ertugliflozin, which can enhance its physicochemical properties, such as solubility and manufacturability. This is crucial for developing consistent and effective pharmaceutical dosage forms, such as tablets. NINGBO INNO PHARMCHEM CO.,LTD. ensures that our Ertugliflozin L-Pyroglutamic Acid meets the precise specifications required for these complex formulations, supporting the development of high-quality pharmaceutical intermediates.
The therapeutic potential of Ertugliflozin L-Pyroglutamic Acid extends beyond just blood sugar control. Clinical studies have indicated that SGLT2 inhibitors can also lead to modest weight loss and a reduction in blood pressure, further contributing to the overall cardiovascular health of patients with type 2 diabetes. As a supplier of this critical compound, NINGBO INNO PHARMCHEM CO.,LTD. is proud to facilitate research and development that leads to these significant health benefits. We are committed to providing the building blocks for the next generation of diabetes treatments.
Manufacturing Facilities
Professional Export Experience
to Global Customers
1. 20 years of R&D, manufacturing and sales experience, serving customers in 60 countries and regions around the world;
2. Own R&D laboratory, pilot platform and large-scale production workshop, which can meet the audit requirements of global customers;
3. We can satisfy customers' perfect transition from small scale lab requirements (gram level) to commercialization requirements (hundred tons level).
A: We don't have Minimum Order Quantity, exact quantity should be provided before quotation for us to calculate the exact cost.
A: We don't provide free samples due to lots of request and expensive international courier's cost, we can deduct the sample charge after commercial order placed.
A: Our payment terms: Small or sample order: T/T IN ADVANCE. Commercial order: First order should be by T/T IN ADVANCE or L/C at sight, and following orders T/T 30~90days is acceptable subject to approval of credit application.
